Silo Pharma Inc (SILO) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has announced a share repurchase program, its financial performance remains weak, with declining EPS and gross margins. Technical indicators suggest the stock is overbought, and there are no strong trading signals or significant positive catalysts to justify immediate investment.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 81.369, signaling the stock is overbought. Moving averages are converging, suggesting indecision in the market. The pre-market price is $0.3779, down -0.50%, with key resistance at $0.368 and $0.406, and support at $0.244 and $0.206.

Positive Catalysts

The company has authorized a $1 million share repurchase program, which could enhance investor confidence and potentially boost stock prices.

Neutral/Negative Catalysts

The company's financials are weak, with declining EPS (-45.45% YoY) and gross margin (-116.07% YoY). Additionally, there are no significant insider or hedge fund trading trends, and the stock is currently overbought based on RSI.

Financial Performance

In 2025/Q3, revenue remained flat at $18,025 (0.00% YoY). Net income improved by 19.55% YoY but remains negative at -$1,110,438. EPS dropped by -45.45% YoY to -$0.12, and gross margin fell significantly to -14.77%, down -116.07% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast SILO stock price to rise

Buy

Hold

Sell

Current: 0.366

Low

Averages

High